Clinical trial
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
NCT00496769 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00496769 |
|---|---|
| Title | A Phase III Study of Apixaban in Patients With Atrial Fibrillation |
| Official title | Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial |
| Acronym | AVERROES |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Apixaban, Acetylsalicylic acid |
| Enrollment | 6,421 |
| Start date | Aug 31, 2007 |
| Primary completion | Nov 30, 2010 |
| Completion | May 25, 2017 |
| First posted | Jul 4, 2007 |
| Last update posted | Jun 15, 2018 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland and 24 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: